Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Allan Syms joins DirectorsTalk to discuss a collaboration with FairJourney Biologics. Allan explains what this collaboration will cover, what will it mean for Cizzle Biotech, more about FairJourney and where the main focus will be over the next 6 months.
Cizzle Biotechnology is a UK based developer of A blood test for the early detection of a majority of different forms of lung cancer.
Cizzle Biotechnology plc’s Executive Chairman discusses new Licensing and Partnership MoU for North America, focusing on revenue streams and market expansion.
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to discuss a strategic and exclusive licensing agreement to develop and offer its proprietary test throughout the USA and Canada. Dr. Alan Syms, discusses the
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has signed a non-binding Memorandum of Understanding for a strategic and exclusive licensing agreement to develop and offer its proprietary test for the CIZ1B
Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced that it has undertaken a conditional placing of 31,050,000 new ordinary shares of 0.01p each in the Company at a price of 2 pence per share
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat
Cizzle Biotechnology plc (LON:CIZ) Executive Chairman Dr Allan Syms joins DirectorsTalk Interviews to the completion of its Evaluation Programme with Bio-Techne for Cizzle’s CIZ1B cancer biomarker. Allan reminds us of what the CIZ1B biomarker is, how this
Bio-Techne Corporation (NASDAQ: TECH) and Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, have announced recent progress evaluating specific monoclonal antibodies for Cizzle’s CIZ1B cancer biomarker. Cizzle has successfully completed an evaluation programme aimed at assessing the feasibility of
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced a further update regarding the Company’s put option to sell its 5% economic interest and royalty sharing agreement in the AZD 1656 asset to treat
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced an expansion of its current research programme with the University of York to develop its CIZ1B biomarker technology for early stage cancer diagnosis, and other potential
Cizzle Biotechnology (LON:CIZ), the UK-based diagnostics developer, has announced that it has conditionally raised gross proceeds of £350,000 (before expenses of £17,500) by way of the issue of 16,666,667 new Ordinary Shares at 2.1p per share with
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK-based diagnostics developer, has announced its audited results for the year ended 31 December 2022. Chair’s Statement The Group has continued throughout 2022 in developing a blood test for the
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has announced that following successful results from its current research programme with the University of York, due to end this year, that it has today signed a new research
Cizzle Biotechnology Holdings plc (LON:CIZ), the UK based diagnostics developer, has announced that it has agreed a put option to sell: (i) its 5% economic interest in the commercialisation of the AZD 1656 asset to treat
Cizzle Biotechnology plc (LON:CIZ), the UK-based diagnostics developer, notes the announcement by Conduit Pharmaceuticals Limited that they intend to become a publicly traded company on NASDAQ in the USA via a merger with Murphy Cannon Acquisition
Cizzle Biotechnology Holdings PLC (LON:CIZ), the UK based diagnostics developer, has announced its interim results for the six months ended 30 June 2022. Highlights · On 14 February 2022 the Group announced a royalty acquisition agreement with Conduit
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy
Cizzle Biotechnology plc (LON:CIZ), focused on cancer diagnostics, was spun out of the University of York to exploit the biomarker, variant CIZ1b, for the early detection of different forms of lung cancer. While implementing this strategy
Cizzle Biotechnology plc (LON:CIZ), the UK based diagnostics developer, has provided an update on the Company’s progress to develop antibodies for use in its proprietary early lung cancer tests, and to announce a new project that
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.